“Blossom is democratising access to psychedelic research by presenting papers from a broad range of disciplines in an accessible weekly write-up.”
Whether you're scouting the next breakthrough compound, conducting due diligence, or designing a trial, fragmented data creates blind spots. Efficient execution requires seeing the full picture—instantly.
Manual tracking via spreadsheets, relying on stale datasets, and missing critical signals buried in paywalled journals.
A unified intelligence layer. Real-time trial tracking, comprehensive compound landscaping, and expert-vetted insights to de-risk your strategy.
Freshly decoded research, clinical trial updates, and country snapshots pulled directly from the lab to your screen.
Topic overview
Depression is the most studied indication in psychedelic science, with multiple compounds now in Phase III trials. While the first FDA approvals are projected for 2027, patients currently access care through clinical trials, specialized psilocybin programs, or widespread ketamine and Spravato treatments.
Latest paper
In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.
Latest trial
Phase IIb randomised, double-blind trial (n=96) comparing two doses of psilocybin (25 mg vs 5 mg) plus psychological support; two doses given one month apart with outcomes over 33 weeks in adults with severe GAD.
Country snapshot
A global research hub hosting the ICPR conference and pioneering work at top universities and CROs. Despite strict clinical laws, the Netherlands maintains a unique legal status for psilocybin truffles, supporting a world-leading ecosystem of professional coaching and retreats.
Timeless reports, compound pages, top research papers lists, and more to help you understand the core concepts of psychedelic science.
REPORT
How auditory settings shape the therapeutic experience and clinical outcomes.
TOP PAPERS
A curated list of foundational research for clinicians and researchers.
COMPOUND
Exploring the potential of ibogaine in treating mental health and substance use disorders.
RESEARCH CENTRES
A directory of the institutions and labs leading the field globally.
Explore the full depth of our intelligence layer. Thousands of datapoints across compounds, people, and markets.
Peer-reviewed literature and summaries.
Interventional and observational studies.
Conferences and gatherings to watch.
Evidence by molecule and safety signals.
Clinical signals across disorders.
Themes that connect research and practice.
Policy and access snapshots by market.
Organizations shaping the field.
Researchers, clinicians, and advocates.
Training and education pathways.
Policy shifts, funding, and headlines.
Pricing that scales with you
Choose the plan that fits your research needs. From individual access to enterprise-grade data solutions.
For solo therapists, individual PhD students, and researchers.
USD
per year
For university labs, Ketamine clinic networks, and boutique funds.
USD
per year
For large organizations, pharma companies, and VC funds.
USD
per year